Healthy aging made possible
Phase
Active
Active Teams
Our independent Judging Panels for the XPRIZE Healthspan and FSHD Bonus Prize competition tracks have selected 48 Top Teams to receive a Milestone Award. Click on any team name below to learn more.
Many additional registered teams beyond the Top 48 remain eligible to advance to Semifinals for XPRIZE Healthspan and/or Finals for the FSHD Bonus Prize. Explore all of our Qualified Teams from around the world on the Meet the Teams map: https://www.xprize.org/prizes/healthspan.
TOP 40 XPRIZE HEALTHSPAN SEMIFINALIST TEAMS
Scroll to see more
| About the Team | Team | City | Country | Country flag | Website(s) |
|---|---|---|---|---|---|
| A NEW DIMENSION | San Jose | United States | |||
| We are a group of with over 200 years of combined experience in US/EU pharmaceutical and clinical development, including academic research. We have a experience in the area of bioenergetics and healthspan. Members of the team have been engaged in clinical studies in this area for over a decade and can comfortably and confidently advance this project to commercial outcome. | |||||
| Abe Yoando Pharma Co Ltd | Adachi | Japan | https://corp.abeyoando.co.jp/ | ||
| Founded in 1731 and rooted in the role of overseeing herbal medicine within the Tokugawa Shogunate government, Abe Yoando Pharma merges centuries-old medical expertise with cutting-edge bioscience under 10th generation head Tomonari Abe. By submitting original research to Japan’s Ministry of Health, it became the first company worldwide to secure NMN’s classification as a food product. While collaborating with eight domestic universities, including the University of Tokyo, the company has so far expanded to 12 countries. Leveraging deep historical knowledge with modern day innovation, Abe Yoando Pharma is a leader in the next-generation longevity space. | |||||
| AgelessRx | Ann Arbor | United States | https://agelessrx.com/ | ||
| AgelessRx is a first of its kind longevity platform that offers the highest level of accessibility to treatments that make you feel better as you age. We believe that aging should not be treated as a dreadful inevitability but instead as a puzzle that can be solved, a fight that can be fought—and is worth fighting—just as a disease with a cure. But until now, only the very few could access the best, most effective longevity treatments. We’re here to change that. Because what good is all the progress made in longevity research and therapies if only a select few have the access? Not good enough, if you ask us. | |||||
| ANI Biome | San Francisco | United States | https://ani.ai/ | ||
| ANI is an AI-first longevity company advancing precision therapeutics by integrating multi-agent intelligence, digital biomarkers, and multi-omics profiling to address aging’s systemic dysfunctions. Our approach, AffectoNeuroImmunology (ANI), models aging as a dynamic, interconnected process across affective, neural, and immune networks. Rather than targeting isolated pathways, ANI Biome’s system benchmarks deviations from ideal homeostasis using digital biomarkers, then applies AI-driven interventions to recalibrate biological function. Our lead intervention, AB, is a predictive small-molecule therapy that optimizes gut-immune-mitochondrial interactions through short-chain fatty acid (SCFA) modulation, targeting systemic resilience and biological age reversal. | |||||
| AutoPhagyGO | Suita | Japan | https://autophagygo.com/ | ||
| AutoPhagyGO Inc. is a biotechnology company dedicated to advancing autophagy research and its applications in healthcare and drug discovery. Leveraging cutting-edge technology and collaborations with leading researchers, the company develops innovative solutions to target autophagy-related diseases, including neurodegenerative disorders, cancer, and metabolic conditions. AutoPhagyGO aims to bridge the gap between fundamental autophagy science and practical therapeutic development, driving innovation through proprietary platforms and strategic partnerships. With a strong commitment to scientific excellence, the company strives to unlock the full potential of autophagy for improving human health and longevity. | |||||
| BioAge Labs | Emeryville | United States | https://bioagelabs.com/ | ||
| BioAge is a clinical-stage biopharmaceutical company pioneering therapies that target the fundamental biology of human aging to treat metabolic diseases. Our approach is based on analysis of human longevity data to identify key molecular drivers of healthy aging. Our lead program is a potent molecule that targets neuroinflammation—a central mechanism in metabolic aging, and we are also developing novel exercise mimetics to address metabolic disorders. By focusing on pathways revealed through our discovery platform, we aim to develop therapeutics that extend healthspan and transform the treatment of age-related metabolic conditions. | |||||
| BioArmor | Kuala Lumpur | Malaysia | https://www.questincubator.org | ||
| Quest Incubator inspires a new generation of students from each country to enter into XPRIZE competitions for learning and innovative solutions. It promotes both education and incubate new businesses to bring solutions to market. | |||||
| Boston Healthspan Team | Boston | United States | https://www.brighamandwomens.org | ||
| Brigham and Women's Hospital (BWH), a Harvard Medical School teaching affiliate, is internationally recognized for patient care excellence, biomedical research leadership, and healthcare professional education. As the #2 NIH-funded independent research hospital in the US, BWH is renowned for landmark studies including the Nurses' Health Study and Women's Health Initiative, with $876 million in annual research funding. The 793-bed private, not-for-profit hospital serves 46,000 inpatient admissions, 3.5 million ambulatory visits, and 59,000 Emergency Department visits annually. With over 20,000 employees—including 3,000 physicians, 1,000 investigators, and 2,800 nurses—BWH is a founding member of Mass General Brigham Healthcare System, New England's largest integrated healthcare network. BWH's Biomedical Research Institute enhances its global scientific leadership through centralized core and administrative services. Its research is supported by Partners Research Management's 300 staff and customized software tools including PeopleSoft, WorkDay, and InfoEd. | |||||
| Canadian Translational Geroscience Network | Montreal | Canada | https://www.geroscience.ca/ | ||
| The Canadian Translational Geroscience Network, led by Dr. Gustavo Duque, coordinates our multidisciplinary team of leading clinician investigators in geroscience, geriatrics, immunology, and endocrinology. With more than 150 clinical trials brought to completion, our investigators are international clinical trial methodology leaders and hold key positions in major international initiatives, including the NIH-funded Geroscience Summit and the Global Geroscience Translational Clinical Trials Taskforce. | |||||
| Circadian | San Diego | United States | |||
| We are part of Salk Institute - it is non-profit. | |||||
| Exomed | Mudgee | Australia | |||
| Exomed is an Australian biotech start-up redefining aging by treating it as a biological endpoint rather than an inevitable decline. Our patented oral exosome-based therapeutic leverages regenerative xenogeneic extracellular vesicles (EVs)—inspired by parabiosis research—to restore muscle, immune, and cognitive function. We believe that for aging to be treatable, solutions must be effective, safe, and accessible. Our approach transforms food-grade bovine plasma into a scalable, non-invasive therapy, ensuring global reach. Supported by HMRI, AMPC, CSIRO, and University Research Institutes, we are advancing clinical validation to bring scientifically proven, regenerative medicine to the world—turning longevity science into real-world impact. | |||||
| GI Innovation | Seoul | South Korea | https://www.gi-innovation.com/en/ | ||
| GI Innovation is a South Korean biotechnology company founded on the strength of its GI-SMART platform technology that enables the rapid optimization of diverse biological fusion proteins with excellent characteristics for manufacturing. We have multiple programs in clinical development for cancer and allergic diseases. | |||||
| Goda Lab | Bunkyo City | Japan | https://goda.chem.s.u-tokyo.ac.jp/ | ||
| The team behind this application leads the "Cell Aging Control" Endowed Chair at The University of Tokyo, a program dedicated to evaluating the quality and efficacy of extracellular vesicle-based therapies for regenerative medicine, in collaboration with The University of Tokyo Hospital. With extensive expertise in chemistry, bioengineering, clinical trial organization, management, and execution, as well as a strong background in study coordination, data management, and statistical analysis, the team is well-equipped to deliver on this project. | |||||
| GOQii Sanjeevini | Mumbai | India | https://www.goqii.com | ||
| GOQii Sanjeevini is a leading preventive health-tech company that integrates advanced wearables, personalized coaching, and gamification to drive lasting lifestyle transformations. Combining AI-driven analytics with behavioral science, GOQii Sanjeevini empowers individuals to proactively manage their health, prevent chronic diseases, and extend their healthspan. Inspired by gaming principles, its rewards-driven ecosystem keeps users engaged, making wellness an interactive and motivating experience. By blending technology, real-time coaching, and data-driven insights, GOQii Sanjeevini transforms health management into an enjoyable and sustainable journey, helping millions take control of their well-being and lead healthier, longer lives. | |||||
| Healthy Longevity Clinic | Boca Raton | United States | https://www.healthylongevity.clinic/ | ||
| HealthyLongevity.clinic specializes in the radical extension of healthy, active human life and making it accessible as soon as possible. Their unique advantage is its close connection to LongevityTech.fund portfolio companies and leading aging research institutions worldwide. They have clinics in Prague, Boca Raton, and the Bahamas subsidiary with 25+ professional staff and serving 500+ longevity clients. | |||||
| IHU HealthAge | Toulouse | France | https://ihuhealthage.fr/en/ | ||
| A University Hospital Institute (IHU) is a centre of scientific and medical excellence whose aim is to accelerate the invention of tomorrow’s medicine and improve healthcare. The 4 main missions of an IHU are : Research: by bringing fundamental research closer to clinical concerns Care: by accelerating the transition between research and therapeutic applications Formation: to strengthen the transfer of knowledge Valorization: economic development and innovation | |||||
| Intervene Immune | Los Angeles | United States | https://www.interveneimmune.com | ||
| Intervene Immune focuses on reversing what we consider the single-most important driver of human aging: immunosenescence. With only seed financing so far, we now have interim Phase 2 data confirming the effectiveness of our core treatment in rejuvenating the immune system, improving key aging biomarkers, and improving body composition, physical fitness, and frailty. Our lead clinical program has U.S. patent protection and includes development of a novel growth hormone “bio-better” product. We have potential to greatly expand the already multi-billion-dollar market for this product in the U.S. by extending its use to the prevention and reversal of immunological aging. | |||||
| Japan Longevity Consortium | Tokyo | Japan | |||
| The Japan Longevity Consortium is an interdisciplinary team comprising medical researchers, clinicians, healthcare startup executives, gym operators, and culinary experts. With expertise spanning anti-aging medicine, genetic science, statistics, cell biology, endocrinology, neurology, kinesiology, geriatrics, nephrology, urology, digital therapeutics, and nutrition, the team integrates diverse perspectives to tackle healthspan extension. Team Leader Shigeo Horie, a board-certified expert in urology, nephrology, and endocrinology, brings extensive experience in designing international clinical trials, supported by a collaborative network of professionals from various fields. | |||||
| Kimera Labs | Miami | United States | https://www.kimeralabs.com | ||
| Founded in 2012 by Duncan Ross, PhD, Kimera® Labs is a clinical-stage biopharmaceutical company specializing in large-scale GMP production and isolation of perinatal mesenchymal stem cell (MSC)-derived exosomes for research and clinical use. Manufactured in 28,000 sq ft of FDA inspected laboratories and clean rooms, Kimera’s MSC-derived exosomes allow for more accessible therapeutic interventions and have proven effective in acceleration of wound healing, reducing inflammation, alleviating various neurological diseases, and promoting an extension of health span in various rodent models. | |||||
| Lionheart Health, Inc. | Newport Beach | United States | https://www.lionhearthealthstim.com | ||
| Orange County, CA based Lionheart Health, Inc. has a patented technology platform based on bioelectric controlled protein expressions to reverse aging 20 years inside and out. Their primary business model is to license thriving medspas, sports medicine clinics, vet clinics and longevity focused medical concierge clinics. Via these licenses they receive a 7% gross sales royalty on their service sales with the Lionheart patented software and equipment. Sites have opened in New York, Newport Beach, Santa Barbara, San Diego, Los Angeles, Scottsdale and Mexico. The company has goal to have 124 clinics generating royalty revenues within 60 months. The company has recruited an all-star team for their commercialization launch including co-CEO Scott Hoots whom sold over 235 regenerative medicine franchises during his 4 year tenure as CEO of his previous company QC Kinetix. They also recruited Chad Hacker former VP of Consumer and Digital Marketing for Abbvie Allergan Aesthetics. Tessa Sphar former onboarding specialist leader for Expotential Fitness of Irvine, CA, that opened up over 60 franchise locations during her tenure there, has also joined the team. They have over 500 patent claims covering healthspan longevity and medical aesthetics. Clinical data on over 1000 patients. 5 FDA product clearances for skin and hair regeneration, joint regeneration, sexual health and rapid body toning. The company won the coveted Abbvie Allergan Innovation of the Year in Medical Aesthetics. They are an official 2nd level entrant in the $101 Million Xprize Healthspan Longevity Competition based on 20 years improvement in muscle health, brain health and immune health. Via it's trained certified licensed locations they offer the patented Lionheart Klotho Wellness Program. | |||||
| LogIN (Longevity Innovator) | Sendai | Japan | https://www.renascience.co.jp/en/ | ||
| Our team is a mixed team of physician-scientists with different medical fields from multiple academic institutions and a start-up company listed in the Tokyo Stock Exchange. Most, if not all, members in this application are principal investigators who have conducted 9 clinical trials with the PAI-1 inhibitor TM5614 (the drug of this application). Experts in immunology, metabolism, stem cell biology, and aging biomarkers come together to verify its anti-aging benefits. | |||||
| Longeveron Inc | Miami | United States | https://www.longeveron.com | ||
| Longeveron is a clinical trial-stage biopharmaceutical company with a team of experienced scientists and clinicians actively engaged in the Healthspan task, focusing on aging-related frailty, immune dysfunction, and Alzheimer’s disease. Our investigational product is Lomecel-BTM, a clinical-stage stem cell therapy, that has completed five clinical trials in the USA. The unique properties of Lomecel-BTM indicate potential abilities to repair and rejuvenate muscle, the immune system, and improve brain function in cognitive decline. | |||||
| Immunis | Irvine | United States | https://www.immunisbiomedical.com | ||
| Immunis is a clinical-stage biotech developing stem cell-derived biologics to address age and immune-related diseases. Immune health and metabolic health decline with age, commonly manifesting as muscle atrophy (sarcopenia), obesity and reduced physical function. Our investigational IMM01-STEM therapeutic contains all-natural biomolecules published in aged mouse models to improve muscle mass and strength, enhance immune cell recruitment, increase lean mass, reduce fat mass and increase physical activity. Immunis completed a Phase 1/2a clinical trial testing IMM01-STEM’s safety, tolerability and efficacy in sarcopenic individuals with knee osteoarthritis and is conducting a Phase 2 placebo-controlled study in adults with sarcopenic obesity. | |||||
| Lono jaeyak | Gunsan | South Korea | |||
| Our team of senotherapeutics experts is dedicated to developing the optimal combination of senomorphic and senolytic agents to effectively normalize senescent cells. We have successfully created a technology demonstrating unparalleled efficacy in reversing the aging process within senescent cells. We believe this groundbreaking approach holds the potential to significantly extend both lifespan and healthspan by mitigating age-related phenotypes. | |||||
| MetHealthspan | New York City | United States | https://www.columbia.edu | ||
| University based research center | |||||
| Minicircle | Austin | United States | https://minicircle.io/ | ||
| Minicircle is the gene therapy technology for people to build the future they envision for themselves. | |||||
| Mitochondrial All-Stars | Needham | United States | https://stealthbt.com/our-company/ | ||
| Stealth BioTherapeutics is a small privately held company developing innovative therapies for mitochondrial disorders. Our dedicated team has progressed mitochondria-targeted therapies far along in the clinic, having completed several Phase 2/3 trials in rare and age-related diseases. Stealth's mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need. Stealth is located in the Boston area and has approximately sixty employees. | |||||
| Mitochondrial Bioenergetics and Ketone Utilization | San Diego | United States | |||
| **The MIDR1V3 & Mitargos: Advancing Brain Health** MIDR1V3 and Mitargos unite wellness with purpose, revolutionizing brain bioenergetics. MIDR1V3 offers a clean, fat-based energy beverage to enhance focus, reduce fatigue, and support brain health—while funding neurodegenerative research. Mitargos’ MG-001 therapy targets energy deficits in Alzheimer’s, TBI, and aging, benefiting active military, veterans, and contact sports. Together, they bridge consumer wellness with scientific innovation, redefining brain health and aging solutions through purpose-driven impact. | |||||
| Mito-tags | Palo Alto | United States | |||
| Our team specializes in mitochondrial bioengineering & mitochondrial transplantation for the immune-neuro-cardiovascular axis. | |||||
| NUS Academy for Healthy Longevity | Singapore | Singapore | https://longevityacademy.sg/ | ||
| The NUS Academy for Healthy Longevity, based in Singapore, is dedicated to advancing research and clinical applications in precision geromedicine. Led by Professor Andrea Maier, our multidisciplinary team comprises experts in gerontology, digital health, clinical psychology, and health management innovation. Our laboratory and clinical facilities support cutting-edge research in geromedicine, employing advanced technologies for biological, clinical, and digital phenotyping and biomarker analysis. Through collaborative partnerships, we aim to revolutionize healthy aging and extend healthspan by developing innovative, personalized interventions. | |||||
| NYC-Vita | New York | United States | https://icahn.mssm.edu/ | ||
| NYC-Vita unites more than 30 experts from Mount Sinai's Aging Program with a group of advisors to drive innovations in healthy aging. Our multidisciplinary team integrates expertise in inflammation, muscle biology, and cognitive health with advanced skills in proteomics, genomics, epigenetics, and ex vivo imaging. With a strong basic and clinical research foundation, we are poised to transform scientific insights into therapies that extend human healthspan and counteract physiological decline. | |||||
| Prometheus Cell Team | Shanghai | China | |||
| Our team specializes in age-related diseases, cell and gene therapy, and personalized regenerative medicine. Leveraging resources from Shanghai Tongji Hospital as well as the Chinese National Base for Stem Cell Research, we developed a breakthrough Autologous Rejuvenated Cell (ARC) technology, which reprograms dermal fibroblasts into rejuvenated mesenchymal stem cell-like Prometheus cells. Our goal is to use Prometheus cells to treat age-related medical conditions and even reverse aging. | |||||
| Rejuvenation through Low Frequency Ultrasound | San Antonio | United States | |||
| University lab. | |||||
| RPRGAON-Progeria/PRG S&Tech | Busan | South Korea | |||
| PRG S&Tech, a South Korea-based biotech company specializing in rare disease research and drug development, has been dedicated to studying Hutchinson-Gilford Progeria Syndrome (HGPS), a rare disorder characterized by accelerated aging approximately 10 times faster than normal. Through years of investigation into the pathogenesis of HGPS, we identified Progerin, a mutant form of lamin A protein, as a critical driver of the disease. We developed Progerinin, a small molecule that selectively induces the degradation of Progerin. It is in Phase 2a trial from January 2025 in Boston Children's Hospital. First clinical efficacy data is expected to come by September 2025. | |||||
| Team GlyNAC | Houston | United States | |||
| Baylor College of Medicine is a medical school involved in healthcare, research and education. | |||||
| The Healthy Mind and Body | Saint Louis | United States | https://healthymind.wustl.edu/ | ||
| The Healthy Mind Lab aims to improve health outcomes by studying treatments that promote healthy minds and healthy bodies across your lifespan. | |||||
| TIME TRAVELER | Taito | Japan | https://www.ttraveler.jp/ | ||
| TIME TRAVELER Inc. (TT Inc.) is a startup established to translate the research achievements of Professor Tetsu Akiyama into societal benefits. At TT Inc. are focused on developing inhibitors targeting Neurotrimin (NTM), a membrane-associated and secreted protein implicated in aging, with the aim of extending lifespan and achieving healthy longevity. Curreio Inc. (Curreio) specializes in drug discovery based on structural analysis using cryo-electron microscopy. The company also leverages AI-driven in silico screening technology to design small-molecule compounds using structural analysis data. | |||||
| Timeline | Lausanne | Switzerland | https://www.timeline.com | ||
| Timeline (parent company Amazentis), a pioneering longevity biotech founded at the Swiss Federal Institute of Technology (EPFL), is dedicated to redefining healthspan through its clinically proven, proprietary bioactive technology, Mitopure® (Urolithin A). With over 15 years of research, multiple clinical studies, and 50+ patents, Timeline’s cutting-edge nutrition and skincare solutions support cellular health, muscle function, immune aging, cognitive function, and skin vitality. The company has published its research in top peer-reviewed journals, including Nature Medicine and Nature Metabolism. Backed by Nestlé Health Science and L'Oréal, Timeline aims to extend healthspan by making the science of aging accessible to all. | |||||
| VITA | Barcelona | Spain | https://www.imim.cat/en_index.html | ||
| Fundació Hospital del Mar Research Institute (HMRI) is a leading biomedical research institution in Barcelona, specializing in translational medicine, aging, and neurodegenerative diseases. In collaboration with the Center for Genomic Regulation (CRG) and IrsiCaixa, our team develops innovative therapeutic strategies to extend healthspan by targeting key aging mechanisms. With extensive expertise in clinical trials, biomarker discovery, and pharmacological research, we aim to translate scientific breakthroughs into scalable, accessible health solutions for aging populations worldwide. | |||||
| YOXLO | Oegstgeest | The Netherlands | https://www.yoxlo.com | ||
| YOXLO is a healthspan-extending biotech company developing Youngenine, an innovative nutritional supplement designed to optimize muscle strength, cognition, and immune function. Youngenine features a patented blend of bioactive ingredients that directly target aging processes. As a semifinalist in the XPRIZE Healthspan competition, YOXLO is gaining global visibility and strategic funding opportunities. With a soft launch planned for 2026, a science-backed formula, and HACCP-certified production, YOXLO is pioneering the longevity market. Youngenine is set to become the first supplement with clinically validated potential to slow aging in these three crucial areas. | |||||
Top 8 FSHD Bonus Prize Finalist Teams
Scroll to see more
| About the Team | Team | City | Country | Country flag | Website(s) |
|---|---|---|---|---|---|
| Altay Therapeutics Inc. | San Carlos | United States | https://www.altaytherapeutics.com | ||
| Altay Therapeutics pioneers breakthrough treatments by targeting transcription factors previously considered undruggable. Our innovative drug discovery approach identifies viable drug binding sites and creates highly specific small molecule inhibitors with optimal pharmaceutical properties. Our innovative platform has enabled us to create industry-leading treatments for neuromuscular disorders and cancer, with our lead therapeutic candidate scheduled to begin clinical trials in 2026. | |||||
| ANI Biome | San Francisco | United States | https://ani.ai/ | ||
| ANI is an AI-first longevity company advancing precision therapeutics by integrating multi-agent intelligence, digital biomarkers, and multi-omics profiling to address aging’s systemic dysfunctions. Our approach, AffectoNeuroImmunology (ANI), models aging as a dynamic, interconnected process across affective, neural, and immune networks. Rather than targeting isolated pathways, ANI Biome’s system benchmarks deviations from ideal homeostasis using digital biomarkers, then applies AI-driven interventions to recalibrate biological function. Our lead intervention, AB, is a predictive small-molecule therapy that optimizes gut-immune-mitochondrial interactions through short-chain fatty acid (SCFA) modulation, targeting systemic resilience and biological age reversal. | |||||
| Armatus Bio | Columbus | United States | https://www.armatusbio.com | ||
| Armatus Bio is a preclinical-stage biotechnology company developing vectorized RNAi medicines for autosomal dominant neuromuscular disorders. ARM-201 is a first-in-class drug designed to result in steady-state silencing of toxic DUX4, the genetic cause of facioscapulohumeral muscular dystrophy (FSHD). ARM-201 has completed a robust series of preclinical studies, and the company has begun regulatory engagement with FDA to prepare for human dosing. Based in Columbus, Ohio, Armatus Bio is collaborating with world-renowned gene therapy experts at Nationwide Children’s Hospital. | |||||
| ASAGI Labs | Nagano | Japan | https://asagilabs.or.jp/en | ||
| ASAGI Labs Foundation is a non-profit organization dedicated to promoting basic research on aging. It operates through collaborative projects with companies and philanthropy-based donations. ASAGI Labs Foundation has established a network of academic researchers focused on aging research and collaborates with the for-profit entity ASAGI Labs Inc. to commercialize intellectual property generated from its research. The primary roles of ASAGI Labs Foundation are to advance innovative aging research and support young talent, with a particular focus on the epigenome, inflammation, and the diversity of aging across species. | |||||
| Beat-FSHD | Los Angeles | United States | |||
| Company Description: Beat-FSHD consists of a team of scientists and clinicians working together to develop safer and more effective therapeutic solutions for muscular dystrophies, including facioscapulohumeral muscular dystrophy. Our research portfolio spans the entire translational arc starting with drug discovery and preclinical development to clinical translation. At Beat-FSHD, we strive to deliver medical breakthroughs through our innovative pipeline. | |||||
| Epicrispr Biotechnologies, Inc | South San Francisco | United States | https://epicrispr.com/ | ||
| Epicrispr Biotechnologies is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. Their lead program, EPI-321, aims to address the underlying molecular mechanisms of FSHD. It is delivered to muscle tissue within a single AAV vector (AAVrh74) which has been clinically validated for muscle delivery. Preclinical studies on EPI-321 have demonstrated its ability to robustly suppress pathological expression of the DUX4 gene and reduce muscle cell death. Clinical data is expected in 2025. In addition to a robust internal pipeline, the company partnered with Kite Pharmaceuticals to develop armored CAR-Ts. | |||||
| Modalis Therapeutics Corporation | Tokyo | Japan | https://www.modalistx.com/en/ | ||
| Modalis Therapeutics, founded in 2016 and listed on the Tokyo Stock Exchange, is a forerunner in the field of epigenetic medicine. Modalis’ proprietary CRISPR-GNDM® technology is capable of specifically modulating the expression of disease-relevant genes without introducing double-strand DNA breaks, which has been validated in disease animal models and non-human primates studies. Specializing in genetic disorders affecting the neuromuscular and CNS regions, Modalis's flagship program, MDL101, aims to treat LAMA2-CMD, a severe congenital form of muscular dystrophy to which no effective therapy exists. | |||||
| SNPM / CHU de Nice | Nice | France | |||
| UniversiThe SNPM Research Consortium is a multidisciplinary team dedicated to advancing therapeutics for neuromuscular diseases, with a focus on Facioscapulohumeral Muscular Dystrophy (FSHD1). Our expertise spans molecular biology, immunology, clinical trials, and biomarker-driven precision medicine. We are pioneering IL-6 inhibition as a novel treatment strategy to slow disease progression and improve patient outcomes. Through cutting-edge research, strategic collaborations, and innovative clinical trial designs, we aim to develop the first disease-modifying therapy for FSHD1, with broader implications for aging-related inflammation and muscle preservation. Our mission is to translate scientific breakthroughs into real-world clinical solutions. | |||||